Exploring the Role of the MUTYH Gene in Breast, Ovarian and Endometrial Cancer

Genes (Basel). 2024 Apr 26;15(5):554. doi: 10.3390/genes15050554.

Abstract

Background: MUTYH germline monoallelic variants have been detected in a number of patients affected by breast/ovarian cancer or endometrial cancer, suggesting a potential susceptibility role, though their significance remains elusive since the disease mechanism is normally recessive. Hence, the aim of this research was to explore the hypothesis that a second hit could have arisen in the other allele in the tumor tissue.

Methods: we used Sanger sequencing and immunohistochemistry to search for a second MUTYH variant in the tumoral DNA and to assess protein expression, respectively.

Results: we detected one variant of unknown significance, one variant with conflicting interpretation of pathogenicity and three benign/likely benign variants; the MUTYH protein was not detected in the tumor tissue of half of the patients, and in others, its expression was reduced.

Conclusions: our results fail to demonstrate that germinal monoallelic MUTYH variants increase cancer risk through a LOH (loss of heterozygosity) mechanism in the somatic tissue; however, the absence or partial loss of the MUTYH protein in many tumors suggests its dysregulation regardless of MUTYH genetic status.

Keywords: MUTYH; autosomal dominant; autosomal recessive; breast cancer; germinal; second hit.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • DNA Glycosylases* / genetics
  • Endometrial Neoplasms* / genetics
  • Endometrial Neoplasms* / pathology
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Loss of Heterozygosity
  • Middle Aged
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / pathology

Substances

  • DNA Glycosylases
  • mutY adenine glycosylase

Grants and funding

C.L. and A.A. are supported by ANIA Foundation, ERG number 21.31.